Literature DB >> 21880693

Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.

Daisuke Kitagawa1, Masaki Gouda, Yasuyuki Kirii, Naoyuki Sugiyama, Yasushi Ishihama, Ikuo Fujii, Yugo Narumi, Kensaku Akita, Koichi Yokota.   

Abstract

It is known that some kinase inhibitors are sensitive to the phosphorylation state of the kinase, and therefore those compounds can discriminate between a phosphorylated and unphosphorylated protein. In this study, we prepared two colony stimulating factor-1 receptor (CSF-1R) tyrosine kinase proteins: one highly phosphorylated by autophosphorylation and the other dephosphorylated by phosphatase treatment. These kinases were subjected to an activity-based assay to investigate the effect of their phosphorylation state on the potency of several kinase inhibitors. Dasatinib, sorafenib, PD173074 and staurosporine showed similar inhibition against different phosphorylation states of CSF-1R, but pazopanib, sunitinib, GW2580 and imatinib showed more potent inhibition against dephosphorylated CSF-1R. Binding analysis of the inhibitors to the two different phosphorylation forms of CSF-1R, using surface plasmon resonance spectrometry, revealed that staurosporine bound to both forms with similar affinity, but sunitinib bound to the dephosphorylated form with higher affinity. Thus, these observations suggest that sunitinib binds preferentially to the inactive form, preventing the activation of CSF-1R. Screening against different activation states of kinases should be an important approach for prioritizing compounds and should facilitate inhibitor design.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880693     DOI: 10.1093/jb/mvr112

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  6 in total

1.  MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.

Authors:  Fiona C Brown; Eric Still; Richard P Koche; Christina Y Yim; Sumiko Takao; Paolo Cifani; Casie Reed; Shehana Gunasekera; Scott B Ficarro; Peter Romanienko; Willie Mark; Craig McCarthy; Elisa de Stanchina; Mithat Gonen; Venkatraman Seshan; Patrick Bhola; Conor O'Donnell; Barbara Spitzer; Crystal Stutzke; Vincent-Philippe Lavallée; Josée Hébert; Andrei V Krivtsov; Ari Melnick; Elisabeth M Paietta; Martin S Tallman; Anthony Letai; Guy Sauvageau; Gayle Pouliot; Ross Levine; Jarrod A Marto; Scott A Armstrong; Alex Kentsis
Journal:  Cancer Discov       Date:  2018-02-05       Impact factor: 39.397

Review 2.  Tumour and patient factors in renal cell carcinoma-towards personalized therapy.

Authors:  Ahmed Q Haddad; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

3.  TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells.

Authors:  Jaehee Kim; Juhyun Oh; Hannah M Peterson; Jonathan C T Carlson; Mikael J Pittet; Ralph Weissleder
Journal:  Adv Biol (Weinh)       Date:  2022-06-08

4.  Inhibition of FGF Receptor-1 Suppresses Alcohol Consumption: Role of PI3 Kinase Signaling in Dorsomedial Striatum.

Authors:  Oren Even-Chen; Segev Barak
Journal:  J Neurosci       Date:  2019-08-02       Impact factor: 6.167

5.  Assessing metastasis risk after pre-operative anti-angiogenic therapy.

Authors:  Daniela Biziato; Michele De Palma
Journal:  EMBO Mol Med       Date:  2014-12       Impact factor: 12.137

6.  TNIK inhibition abrogates colorectal cancer stemness.

Authors:  Mari Masuda; Yuko Uno; Naomi Ohbayashi; Hirokazu Ohata; Ayako Mimata; Mutsuko Kukimoto-Niino; Hideki Moriyama; Shigeki Kashimoto; Tomoko Inoue; Naoko Goto; Koji Okamoto; Mikako Shirouzu; Masaaki Sawa; Tesshi Yamada
Journal:  Nat Commun       Date:  2016-08-26       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.